Clozapine facilitates sustained improvement in psychotic symptoms with a subsequent cascade of effects on functioning and quality of life.

BACKGROUND

Clozapine is the only evidence-based medication for treatment-resistant schizophrenia (TRS), yet little is known how long-term symptom response relates to everyday functioning and quality of life (QOL). We conducted a longitudinal study to determine whether symptomatic improvement with clozapine continues over the course of treatment and impacts subsequent functioning and QOL.

METHODS

Patients on clozapine were followed over 2014-2025, including those newly initiating clozapine ("new-starts") and those who initiated prior to the study ("prior-starts"). They were rated serially on the Positive and Negative Symptoms Scale (PANSS) and the Personal and Social Performance (PSP) scale, and self-reported their QOL on the World Health Organization QOL (WHOQOL) scale. Trajectories of outcomes were examined using hierarchical linear modeling. To identify potential temporal pathways, we applied correlated time series with lagged analyses, testing whether symptom time-courses predicted later functioning and QOL.

RESULTS

82 patients (25 new-starts, 57 prior-starts) provided data. Positive symptoms showed sustained improvement over time in both groups. Although functioning and QOL did not improve in the overall sample, lower baseline PANSS scores predicted higher concurrent PSP scores. Sequential lagged analyses indicated a temporal cascade of lower symptoms at each time-point x predicting higher functioning at x+1, which predicted improved QOL at x+2.

CONCLUSIONS

In TRS patients on clozapine, psychotic symptoms improved and correlated with downstream functioning and QOL. Modeling temporal relationships with lagged analyses, we demonstrated that clozapine was associated with sustained improvement in psychosis regardless of time since initiation, possibly facilitating long-term recovery through sequential effects on clinical, functional, and QOL domains.